Long-Acting Injectable HIV Treatment Shows Promise In Clinical Trials

Associated Press: J&J, ViiV: 2 injections every month or 2 could control HIV
“Preliminary testing of two long-acting injectable drugs indicates it might be possible to keep HIV at bay indefinitely with injections every month or two. Johnson & Johnson and partner ViiV Healthcare, which specializes in HIV drugs, on Tuesday announced results from the first 32 weeks of the planned 96-week study, which combines one drug from each company…” (Johnson, 11/3).

Reuters: Bi-monthly injection blocks HIV in study from J&J and GSK
“…Paul Stoffels, J&J’s head of pharmaceuticals, said the finding offered a potentially ‘transformational’ way to fight HIV, if the result is confirmed in larger final-stage trials. He believes the combination could be on the market by 2020…” (11/3).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.